Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Designs of drug-combination phase I trials in oncology: a systematic review of the literature journalArticle 2015 Riviere, M. K.; Le Tourneau, C.; Paoletti, X.; Dubois, F.; Zohar, S.
Reply to V.P. Retel et al, D. Gauchan et al, and C. Rahilly-Tierney et al journalArticle 2015 Bonastre, J.; Marguet, S.; Lueza, B.; Michiels, S.; Delaloge, S.; Saghatchian, M.
Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role? journalArticle 2016 Ou, D.; Levy, A.; Blanchard, P.; Nguyen, F.; Garberis, I.; Casiraghi, O.; Scoazec, J. Y.; Janot, F.; Temam, S.; Deutsch, E.; Tao, Y.
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence journalArticle 2016 Ignatiadis, M.; Azim, H. A.; Desmedt, C.; Veys, I.; Larsimont, D.; Salgado, R.; Lyng, M. B.; Viale, G.; Leyland-Jones, B.; Giobbie-Hurder, A.; Kammler, R.; Dell'Orto, P.; Rothe, F.; Laios, I.; Ditzel, H. J.; Regan, M. M.; Piccart, M.; Michiels, S.; Sotiriou, C.
Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy journalArticle 2018 Ou, D.; Garberis, I.; Adam, J.; Blanchard, P.; Nguyen, F.; Levy, A.; Casiraghi, O.; Gorphe, P.; Breuskin, I.; Janot, F.; Temam, S.; Scoazec, J. Y.; Deutsch, E.; Tao, Y.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial journalArticle 2015 van den Berg, H.; Paulussen, M.; Le Teuff, G.; Judson, I.; Gelderblom, H.; Dirksen, U.; Brennan, B.; Whelan, J.; Ladenstein, R. L.; Marec-Berard, P.; Kruseova, J.; Hjorth, L.; Kuhne, T.; Brichard, B.; Wheatley, K.; Craft, A.; Juergens, H.; Gaspar, N.; Le Deley, M. C.; Euro, Ewing Group
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials journalArticle 2016 Le Tourneau, C.; Kamal, M.; Tsimberidou, A. M.; Bedard, P.; Pierron, G.; Callens, C.; Rouleau, E.; Vincent-Salomon, A.; Servant, N.; Alt, M.; Rouzier, R.; Paoletti, X.; Delattre, O.; Bieche, I.
The Use of Indirect Comparisons in Medicines Evaluation for their Access To Reimbursement by the Has journalArticle 2015 Guichard, M.; D'Andon, A.; Rumeau Pichon, C.; Borget, I.
Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial journalArticle 2018 Bahig, H.; Yuan, Y.; Mohamed, A. S. R.; Brock, K. K.; Ng, S. P.; Wang, J.; Ding, Y.; Hutcheson, K.; McCulloch, M.; Balter, P. A.; Lai, S. Y.; Al-Mamgani, A.; Sonke, J. J.; van der Heide, U. A.; Nutting, C.; Li, X. A.; Robbins, J.; Awan, M.; Karam, I.; Newbold, K.; Harrington, K.; Oelfke, U.; Bhide, S.; Philippens, M. E. P.; Terhaard, C. H. J.; McPartlin, A. J.; Blanchard, P.; Garden, A. S.; Rosenthal, D. I.; Gunn, G. B.; Phan, J.; Cazoulat, G.; Aristophanous, M.; McSpadden, K. K.; Garcia, J. A.; van den Berg, C. A. T.; Raaijmakers, C. P. J.; Kerkmeijer, L.; Doornaert, P.; Blinde, S.; Frank, S. J.; Fuller, C. D.
The association between coffee consumption and bladder cancer in the bladder cancer epidemiology and nutritional determinants (BLEND) international pooled study journalArticle 2019 Yu, E. Y.; Wesselius, A.; van Osch, F.; Stern, M. C.; Jiang, X.; Kellen, E.; Lu, C. M.; Pohlabeln, H.; Steineck, G.; Marshall, J.; Allam, M. F.; La Vecchia, C.; Johnson, K. C.; Benhamou, S.; Zhang, Z. F.; Bosetti, C.; Taylor, J. A.; Zeegers, M. P.
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice journalArticle 2016 Michiels, S.; Ternes, N.; Rotolo, F.
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial journalArticle 2018 Tao, Y.; Auperin, A.; Sire, C.; Martin, L.; Khoury, C.; Maingon, P.; Bardet, E.; Kaminsky, M. C.; Lapeyre, M.; Chatellier, T.; Alfonsi, M.; Pointreau, Y.; Jadaud, E.; Géry, B.; Zawadi, A.; Tourani, J. M.; Laguerre, B.; Coutte, A.; Racadot, S.; Hasbini, A.; Malaurie, E.; Borel, C.; Meert, N.; Cornely, A.; Ollivier, N.; Casiraghi, O.; Sun, X. S.; Bourhis, J.
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study journalArticle 2018 Gaspar, N.; Occean, B. V.; Pacquement, H.; Bompas, E.; Bouvier, C.; Brisse, H. J.; Castex, M. P.; Cheurfa, N.; Corradini, N.; Delaye, J.; Entz-Werle, N.; Gentet, J. C.; Italiano, A.; Lervat, C.; Marec-Berard, P.; Mascard, E.; Redini, F.; Saumet, L.; Schmitt, C.; Tabone, M. D.; Verite-Goulard, C.; Le Deley, M. C.; Piperno-Neumann, S.; Brugieres, L.; Sfce; Gsf, Geto; group, Unicancer sarcoma
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature journalArticle 2015 Marous, M.; Bieche, I.; Paoletti, X.; Alt, M.; Razak, A. R.; Stathis, A.; Kamal, M.; Le Tourneau, C.
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer journalArticle 2018 Criscitiello, C.; Bayar, M. A.; Curigliano, G.; Symmans, F. W.; Desmedt, C.; Bonnefoi, H.; Sinn, B.; Pruneri, G.; Vicier, C.; Pierga, J. Y.; Denkert, C.; Loibl, S.; Sotiriou, C.; Michiels, S.; André, F.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience journalArticle 2019 Assi, T.; Cavalcanti, A.; Le Cesne, A.; Faron, M.; Honart, J. F.; Hadiji, A.; Camuzard, O.; Ibrahim, T.; LePechoux, C.; Mir, O.; Dumont, S.; Terrier, P.; Adam, J.; Honore, C.
Follow-up of differentiated thyroid cancer - what should (and what should not) be done journalArticle 2018 Lamartina, L.; Grani, G.; Durante, C.; Borget, I.; Filetti, S.; Schlumberger, M.
Human metapneumovirus in patients hospitalized with acute respiratory infections: A meta-analysis journalArticle 2016 Lefebvre, A.; Manoha, C.; Bour, J. B.; Abbas, R.; Fournel, I.; Tiv, M.; Pothier, P.; Astruc, K.; Aho-Glele, L. S.
Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma journalArticle 2015 Diouf, M.; Bonnetain, F.; Barbare, J. C.; Bouche, O.; Dahan, L.; Paoletti, X.; Filleron, T.
Efficacy of vaccination against HPV infection to prevent cervical cancer in France journalArticle 2015 Ribassin-Majed, L.; Hill, C.; Lounes, R.
Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in Europe journalArticle 2015 Bölling, T.; Braun-Munzinger, G.; Burdach, S.; Calaminus, G.; Craft, A.; Delattre, O.; Deley, M. C.; Dirksen, U.; Dockhorn-Dworniczak, B.; Dunst, J.; Engel, S.; Faldum, A.; Fröhlich, B.; Gadner, H.; Göbel, U.; Gosheger, G.; Hardes, J.; Hawkins, D. S.; Hjorth, L.; Hoffmann, C.; Kovar, H.; Kruseova, J.; Ladenstein, R.; Leuschner, I.; Lewis, I. J.; Oberlin, O.; Paulussen, M.; Potratz, J.; Ranft, A.; Rössig, C.; Rübe, C.; Sauer, R.; Schober, O.; Schuck, A.; Timmermann, B.; Tirode, F.; van den Berg, H.; van Valen, F.; Vieth, V.; Willich, N.; Winkelmann, W.; Whelan, J.; Womer, R. B.
Comment on "Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis", published in Eur J Cancer 51 (2015), 1570-1579 journalArticle 2016 Blanchard, P.; Ribassin-Majed, L.; Lee, A.; Pignon, J. P.
The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study journalArticle 2019 Johansson, M.; Carreras-Torres, R.; Scelo, G.; Purdue, M. P.; Mariosa, D.; Muller, D. C.; Timpson, N. J.; Haycock, P. C.; Brown, K. M.; Wang, Z.; Ye, Y.; Hofmann, J. N.; Foll, M.; Gaborieau, V.; Machiela, M. J.; Colli, L. M.; Li, P.; Garnier, J. G.; Blanche, H.; Boland, A.; Burdette, L.; Prokhortchouk, E.; Skryabin, K. G.; Yeager, M.; Radojevic-Skodric, S.; Ognjanovic, S.; Foretova, L.; Holcatova, I.; Janout, V.; Mates, D.; Mukeriya, A.; Rascu, S.; Zaridze, D.; Bencko, V.; Cybulski, C.; Fabianova, E.; Jinga, V.; Lissowska, J.; Lubinski, J.; Navratilova, M.; Rudnai, P.; Benhamou, S.; Cancel-Tassin, G.; Cussenot, O.; Weiderpass, E.; Ljungberg, B.; Tumkur Sitaram, R.; Haggstrom, C.; Bruinsma, F.; Jordan, S. J.; Severi, G.; Winship, I.; Hveem, K.; Vatten, L. J.; Fletcher, T.; Larsson, S. C.; Wolk, A.; Banks, R. E.; Selby, P. J.; Easton, D. F.; Andreotti, G.; Beane Freeman, L. E.; Koutros, S.; Mannisto, S.; Weinstein, S.; Clark, P. E.; Edwards, T. L.; Lipworth, L.; Gapstur, S. M.; Stevens,
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies journalArticle 2016 Postel-Vinay, S.; Aspeslagh, S.; Lanoy, E.; Robert, C.; Soria, J. C.; Marabelle, A.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial journalArticle 2015 Le Tourneau, C.; Delord, J. P.; Goncalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Tredan, O.; Massiani, M. A.; Mauborgne, C.; Armanet, S.; Servant, N.; Bieche, I.; Bernard, V.; Gentien, D.; Jezequel, P.; Attignon, V.; Boyault, S.; Vincent-Salomon, A.; Servois, V.; Sablin, M. P.; Kamal, M.; Paoletti, X.; investigators, Shiva
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial journalArticle 2016 Blanchard, P.; Faivre, L.; Lesaunier, F.; Salem, N.; Mesgouez-Nebout, N.; Deniau-Alexandre, E.; Rolland, F.; Ferrero, J. M.; Houede, N.; Mourey, L.; Theodore, C.; Krakowski, I.; Berdah, J. F.; Baciuchka, M.; Laguerre, B.; Davin, J. L.; Habibian, M.; Culine, S.; Laplanche, A.; Fizazi, K.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) journalArticle 2015 Gourgou-Bourgade, S.; Cameron, D.; Poortmans, P.; Asselain, B.; Azria, D.; Cardoso, F.; A'Hern, R.; Bliss, J.; Bogaerts, J.; Bonnefoi, H.; Brain, E.; Cardoso, M. J.; Chibaudel, B.; Coleman, R.; Cufer, T.; Dal Lago, L.; Dalenc, F.; De Azambuja, E.; Debled, M.; Delaloge, S.; Filleron, T.; Gligorov, J.; Gutowski, M.; Jacot, W.; Kirkove, C.; MacGrogan, G.; Michiels, S.; Negreiros, I.; Offersen, B. V.; Penault Llorca, F.; Pruneri, G.; Roche, H.; Russell, N. S.; Schmitt, F.; Servent, V.; Thürlimann, B.; Untch, M.; van der Hage, J. A.; van Tienhoven, G.; Wildiers, H.; Yarnold, J.; Bonnetain, F.; Mathoulin-Pélissier, S.; Bellera, C.; Dabakuyo-Yonli, T. S.
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment journalArticle 2017 Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C.
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients journalArticle 2016 Deutsch, E.; Haie-Meder, C.; Bayar, M. A.; Mondini, M.; Laporte, M.; Mazeron, R.; Adam, J.; Varga, A.; Vassal, G.; Magne, N.; Chargari, C.; Lanoy, E.; Pautier, P.; Levy, A.; Soria, J. C.
Proton versus photon radiation-induced cell death in head and neck cancer cells journalArticle 2019 Wang, L.; Han, S.; Zhu, J.; Wang, X.; Li, Y.; Wang, Z.; Lin, E.; Wang, X.; Molkentine, D. P.; Blanchard, P.; Yang, Y.; Zhang, R.; Sahoo, N.; Gillin, M.; Zhu, X. R.; Zhang, X.; Myers, J. N.; Frank, S. J.
Prevalence of burnout, depression and job satisfaction among French senior and resident radiation oncologists journalArticle 2018 Lazarescu, I.; Dubray, B.; Joulakian, M. B.; Blanchard, P.; Chauvet, B.; Mahe, M. A.; Mornex, F.; Rocher, F.; Thureau, S.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer journalArticle 2015 Nascimento, C.; Borget, I.; Al Ghuzlan, A.; Deandreis, D.; Hartl, D.; Lumbroso, J.; Berdelou, A.; Lepoutre-Lussey, C.; Mirghani, H.; Baudin, E.; Schlumberger, M.; Leboulleux, S.
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients journalArticle 2016 Deutsch, E.; Haie-Meder, C.; Bayar, M. A.; Mondini, M.; Laporte, M.; Mazeron, R.; Adam, J.; Varga, A.; Vassal, G.; Magne, N.; Chargari, C.; Lanoy, E.; Pautier, P.; Levy, A.; Soria, J. C.
Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? journalArticle 2017 Bossi, A.; Mottet, N.; Blanchard, P.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer journalArticle 2019 Apolle, R.; Appold, S.; Bijl, H. P.; Blanchard, P.; Bussink, J.; Faivre-Finn, C.; Khalifa, J.; Laprie, A.; Lievens, Y.; Madani, I.; Ruffier, A.; de Ruysscher, D.; van Elmpt, W.; Troost, E. G. C.
Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death journalArticle 2018 Krol, A.; Tournigand, C.; Michiels, S.; Rondeau, V.